SCHEMBL9687537

SCHEMBL9687537

O=C(Cl)C(c1ccccc1)S(=O)(=O)O

nearest known ligand 0.70

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SRC P12931 3/20 0.70
PTPN1 P18031 3/20 0.47
PTPN6 P29350 3/20 0.47
PTPN11 Q06124 3/20 0.47
ALDH1A1 P00352 1/20 0.47
ACP1 P24666 10/20 0.45
PTPN12 Q05209 4/20 0.45
PTPN13 Q12923 3/20 0.45
SSU72 Q9NP77 3/20 0.45
PTPN7 P35236 2/20 0.45
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10671823 1.00 SRC (0.70) SRCPTPN1PTPN6PTPN11ALDH1A1
SCHEMBL9912817 1.00 SRC (0.70) SRCPTPN1PTPN6PTPN11ALDH1A1
SCHEMBL11721467 0.83 SRC (0.53) SRCPTPN1PTPN6PTPN11ALDH1A1
SCHEMBL11166146 0.83 SRC (1.00) SRCPTPN1PTPN6PTPN11ALDH1A1
SCHEMBL20869602 0.83 SRC (1.00) SRCPTPN1PTPN6PTPN11ALDH1A1
SCHEMBL9912818 0.83 SRC (1.00) SRCPTPN1PTPN6PTPN11ALDH1A1
SCHEMBL11211392 0.82 SRC (0.48) SRCPTPN1PTPN6PTPN11ALDH1A1
SCHEMBL27467301 0.82 SRC (0.52) SRCPTPN1PTPN6PTPN11ALDH1A1
SCHEMBL5848473 0.82 SRC (0.52) SRCALDH1A1CYP2D6CYP2C19LMNA
SCHEMBL11211690 0.81 SRC (0.47) SRCALDH1A1ACP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113980033-B Synthesis process of D-sulbenicillin sodium 海南海灵化学制药有限公司 2023-02-28 CN claimed
CN-113980033-A Synthesis process of D-sulbenicillin sodium 海南海灵化学制药有限公司 2022-01-28 CN claimed
CN-113980033-B Synthesis process of D-sulbenicillin sodium 海南海灵化学制药有限公司 2023-02-28 CN disclosed
CN-113980033-B Synthesis process of D-sulbenicillin sodium 海南海灵化学制药有限公司 2023-02-28 CN disclosed
CN-113980033-A Synthesis process of D-sulbenicillin sodium 海南海灵化学制药有限公司 2022-01-28 CN disclosed
CN-113980033-A Synthesis process of D-sulbenicillin sodium 海南海灵化学制药有限公司 2022-01-28 CN disclosed
CN-108373475-B Preparation method of sulbenicillin sodium 山东四环药业股份有限公司 2020-12-01 CN disclosed
CN-107641130-B Preparation method of D-sulbenicillin sodium 中国医药集团总公司四川抗菌素工业研究所 2020-05-29 CN disclosed
US-20180170862-A1 PROTEIN TYROSINE PHOSPHATASES OR SHP2 INHIBITORS AND USES THEREOF INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2018-06-21 US disclosed
US-20180170861-A1 SMALL MOLECULE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES AND USED THEREOF INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2018-06-21 US disclosed
CN-106317075-A Preparing method of Cefsulodin 中国医药集团总公司四川抗菌素工业研究所 2017-01-11 CN disclosed
US-4139618-A Cephalosporin type antibacterials SYNTEX (U.S.A.) INC. (US) 1979-02-13 US disclosed
US-4086423-A CEPHALOSPORINS, CYCLOADDITION OF GLYCINE DERIVATIVE TO THIAZINE COMPOUND MERCK & CO., INC. (US) 1978-04-25 US disclosed
US-4065619-A ANTIBIOTIC TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) 1977-12-27 US disclosed
US-4064343-A ANTIBIOTICS ELI LILLY AND COMPANY (US) 1977-12-20 US disclosed
US-4049806-A Cephalosporin type antibacterials SYNTEX (U.S.A.) INC. (US) 1977-09-20 US disclosed
US-4029656-A ANTIBACTERIAL TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) 1977-06-14 US disclosed
US-4011214-A 3-(MORPHOLINOALKOXYIMINOMETHYL)CEPHEM COMPOUNDS TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) 1977-03-08 US disclosed
US-3988327-A 7-(α-SULFOACYLAMIDO)CEPHALOSPORANIC ACIDS TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) 1976-10-26 US disclosed
US-3962227-A ANTIBIOTICS ELI LILLY AND COMPANY (US) 1976-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180170861-A1 SMALL MOLECULE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES AND USED THEREOF PTPA, EPM2A, PTPRA SRC 201/4885PTPN1 33/4885PTPN6 28/4885
US-20180170862-A1 PROTEIN TYROSINE PHOSPHATASES OR SHP2 INHIBITORS AND USES THEREOF PTPA, PTPRA, PTPRCAP SRC 119/4885PTPN1 22/4885PTPN6 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.